A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523

Trial Profile

A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs HMPL 523 (Primary)
  • Indications Autoimmune disorders; Rheumatoid arthritis
  • Focus Adverse reactions; First in man
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 06 Dec 2016 According to a Hutchison MediPharma media release, data from this trial was presented at the Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals.
    • 14 Nov 2016 Results published in the Chi Med Media Release
    • 14 Nov 2016 Data from this trial will be presented at the Annual Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals as reported by a Chi Med media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top